Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Posted by Francis Steltz on Aug 1st, 2026

Estrella Immunopharma, Inc. (NASDAQ:ESLA – Get Free Report) was the recipient of a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 54,453 shares, a drop of 38.9% from the June 30th total of 89,082 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 45,733 shares, the short-interest ratio is presently 1.2 days.

Estrella Immunopharma Stock Performance

NASDAQ:ESLA opened at $0.71 on Friday. Estrella Immunopharma has a 1 year low of $0.69 and a 1 year high of $3.15. The stock has a market cap of $30.71 million, a P/E ratio of -2.10 and a beta of 0.85. The stock has a 50-day simple moving average of $0.96 and a 200-day simple moving average of $1.15.

Estrella Immunopharma (NASDAQ:ESLA – Get Free Report) last announced its quarterly earnings results on Saturday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. On average, equities research analysts predict that Estrella Immunopharma will post -0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Get Our Latest Report on ESLA

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ESLA. Renaissance Technologies LLC grew its stake in shares of Estrella Immunopharma by 1,045.7% in the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock valued at $191,000 after purchasing an additional 111,779 shares during the last quarter. Marshall Wace LLP purchased a new position in Estrella Immunopharma during the fourth quarter worth about $88,000. XTX Topco Ltd increased its position in Estrella Immunopharma by 376.9% during the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Estrella Immunopharma in the 4th quarter valued at approximately $43,000. Finally, State Street Corp raised its position in Estrella Immunopharma by 93.5% in the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after acquiring an additional 20,900 shares in the last quarter. 0.35% of the stock is owned by hedge funds and other institutional investors.

About Estrella Immunopharma

(Get Free Report)

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.